Pangaea Oncology, S.A.

PANG

ES0105221008

Biotechnology & Medical Research

Market Closed - BME Other stock markets 10:00:15 2024-04-19 am EDT			5-day change	1st Jan Change
1.78 ^EUR	0.00%		-4.30%	-3.26%

2023	Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Pangaea Oncology, S.A. announced that it has received €2.5 million in funding

August 09, 2018

On August 10, 2018, Pangaea Oncology, S.A. (BME:PANG) closed the transaction. The transaction was fully subscribed.

Latest news about Pangaea Oncology, S.A.

Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-30	CI
Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-27	CI
Pangaea Oncology, S.A. announced that it expects to receive €3.875 million in funding	22-05-12	CI
Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-10-28	CI
Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. from HERSOL XXI, SL for €1.5 million.	20-10-12	CI
Pangaea Oncology, S.A. announced that it has received €2.5 million in funding	18-08-09	CI
Pangaea Oncology, S.A. announced that it expects to receive €2.5 million in funding	18-06-13	CI
HERSOL XXI, SL acquired an additional 0.6% stake in Pangaea Oncology, S.A. from director of Grupo Pikolin, S.L. for €0.15 million.	18-01-02	CI
GrupoPikolin, S.L. acquired 24.94% stake in Pangaea Oncology, S.A. from Mercantile Ebrosol Inversiones, S.L.U.	17-01-02	CI

Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Companyâs activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Ratings for Pangaea Oncology, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PANGAEA ONCOLOGY, S.A.	-3.26%	55.89M
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B

Other Biotechnology & Medical Research